Pharmascience
6111 Royalmount Avenue, Montréal, Québec, H4P 2T4, Canada
Overview
Pharmascience is a generic drugs company that committed to the breadth and diversity of its product portfolio, which includes prescription, over-the-counter, and generic medications as well as medical devices that adhere to the strictest international regulatory standards. Additionally, they provide a vast array of services, including manufacturing and contract research and development.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biopharma
- Manufacturing
- Pharmaceutical
Investment portfolio
- RDD Pharma
Participated · Series B · Nov 2017
RDD Pharma is a specialty pharmaceutical company focused on fast-track development and commercialization of therapeutics for anorectal diseases and lower-gastrointestinal tract disorders. The company has two clinical-stage products: RDD-1219 for chronic anal fissure, currently enrolling patients in a multicenter European Phase 3 study with 300 patients already enrolled, and RDD-0315 for fecal incontinence, an indication with no approved prescription products. Two pre-clinical assets target pruritus ani and radiation colitis/proctitis. Led by CEO Jason Laufer, the company is based in New York and Tel Aviv. RDD Pharma intends to use the funds to advance its programs globally in anal fissure, fecal incontinence, radiation colitis/proctitis and pruritus ani. The company recently completed a Series B financing to support these plans.
Team
No current team members are available.